ClinicalTrials.gg
RecruitingNCT06736704Updated Mar 13, 2026

SNV4818 in Participants With Advanced Solid Tumors

A Phase 1/2 interventional study of SNV4818 and Fulvestrant in Advanced Solid Tumors, sponsored by Pikavation Therapeutics, Inc.. Recruiting at 12 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-03-13.

Sponsored by Pikavation Therapeutics, Inc. · Phase 1/2, Interventional, and Treatment

From the registry’s dates

  • Started Feb 2025; still recruiting 1 year 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
320
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Study summary

This study is testing a new medicine, SNV4818, for people with advanced cancers. The researchers want to find out if SNV4818 is safe, well-tolerated, and effective in treating solid tumors. They are investigating different doses in order to find the safest and most effective one.

02

Conditions studied

  • Advanced Solid Tumors
03

In context

Lead sponsor

This is the only study on the registry with Pikavation Therapeutics, Inc. as lead sponsor.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Advanced or solid tumor with an activating PIK3CA mutation.
  • to or intolerant of available therapies
  • Disease measurable by 1.1 criteria, or disease evaluable by tumor biomarkers in blood.
  • (ECOG) performance status of 0 or 1

Exclusion criteria

Exclusion Criteria:

  • Diagnosis of a primary CNS
  • Active or carcinomatous meningitis
  • Type 1 diabetes mellitus or uncontrolled type 2 diabetes mellitus
  • Inadequate organ function
  • abnormalities, including ≥ 470 ms
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
320 participants (estimated)

Study arms

  • Experimental
    SNV4818 Monotherapy

    Participants will receive oral, daily doses of SNV4818 as a single agent as part of either dose escalation or dose expansion cohorts. The SNV4818 dose level participants receive will depend upon the study part to which they are assigned. Dose escalation participants will be assigned to small cohorts of ascending SNV4818 dose levels. Dose expansion participants will receive one of the SNV4818 dose levels recommended for further evaluation.

    Drug: SNV4818

  • Experimental
    SNV4818+Fulvestrant Combination

    Participants will receive oral, daily doses of SNV4818 in combination with a standard dose of Fulvestrant as part of either dose escalation or dose expansion cohorts.. The SNV4818 dose level participants receive will depend upon the study part to which they are assigned. Dose escalation participants will be assigned to small cohorts of ascending SNV4818 dose levels. Dose expansion participants will receive one of the SNV4818 dose levels recommended for further evaluation.

    Drug: SNV4818 · Drug: Fulvestrant

  • Experimental
    SNV4818+Palbociclib+Fulvestrant Combination

    Participants will receive oral, daily doses of SNV4818 in combination with a standard doses of Palbociclib and Fulvestrant as part of either dose escalation or dose expansion cohorts.. The SNV4818 dose level participants receive will depend upon the study part to which they are assigned. Dose escalation participants will be assigned to small cohorts of ascending SNV4818 dose levels. Dose expansion participants will receive one of the SNV4818 dose levels recommended for further evaluation.

    Drug: SNV4818 · Drug: Fulvestrant · Drug: Palbociclib

Interventions

  • DrugSNV4818

    SNV4818 is a tablet taken orally. Dose and frequency are dependent upon treatment arm.

  • Fulvestrant is administered via an intramuscular injection. It will be given at a dose of 500 mg (2-250 mg/5 mL injections)

    Also known as: Faslodex

  • Palbociclib tablets will be administered by mouth on days 1-21 of a 28 day cycle. The Palbociclib starting dose will be 125 mg once-daily

    Also known as: Ibrance

06

What researchers measure

Primary outcomes

  1. Incidence of dose limiting toxicities (DLTs)

    -Number of participants experiencing protocol-defined DLTs (Part 1A and 2A only)

    Time frame: First 28 days of study treatment

  2. Treatment Emergent Adverse Events (TEAEs)

    Incidence and frequency of TEAEs

    Time frame: From first SNV4818 dose through approximately 30 days following the last SNV4818 dose

Secondary outcomes

  1. Maximum observed plasma concentration of SNV4818

    Cmax

    Time frame: After 4 weeks (1 cycle) of study treatment

  2. Time to reach the maximum observed plasma concentration of SNV4818

    Tmax

    Time frame: After 4 weeks (1 cycle) of study treatment

  3. Area Under Plasma Concentration (AUC) Time Curve of SNV4818

    AUC0-t

    Time frame: After 4 weeks (1 cycle) of study treatment

  4. Half-life of SNV4818

    t1/2

    Time frame: After 4 weeks (1 cycle) of study treatment

  5. Area Under Plasma Concentration (AUC) Time Curve of SNV4818 extrapolated to infinity

    AUC0-infinity

    Time frame: After 1 day of study treatment

  6. Apparent oral clearance of SNV4818

    CL/F

    Time frame: After 4 weeks (1 cycle) of study treatment

  7. Apparent volume of distribution of SNV4818

    Vz/F

    Time frame: After 4 weeks (1 cycle) of study treatment

  8. Overall response rate (ORR)

    The proportion of participants who achieve a best overall response (BOR) of complete response (CR) or partial response (PR), based on RECIST 1.1 criteria

    Time frame: After 8 weeks on study treatment

  9. Disease control rate (DCR)

    The proportion of participants who have a best overall response (BOR) of stable disease (SD) or better

    Time frame: After 8 weeks on study treatment

  10. Duration of response (DOR)

    The time interval between an assessment of partial response (PR) or better and disease progression or death due to any cause.

    Time frame: Up to approximately 2 years

07

Study locations

12 of 12 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Feb 2025 (actual). Primary completion is estimated for Apr 2027, 26 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 12, 2024
First posted
Dec 17, 2024
StartActual
Feb 20, 2025
Primary completionEst.
Apr 2027
CompletionEst.
Jun 2027
Last update
Mar 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 13, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06736704
Lead sponsor
Pikavation Therapeutics, Inc.
Responsible party
Sponsor
First posted
Dec 17, 2024
Start date
Feb 20, 2025
Primary completion
Apr 2027 (estimated)
Completion
Jun 2027 (estimated)
Last update
Mar 13, 2026

Study contacts

Robert Casper
Contact
rcasper@synnovationtx.com
443-764-9527

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion